The global sterile injectables CDMO market size is calculated at USD 4.73 billion in 2025 and is forecasted to reach around USD 10.91 billion by 2034, accelerating at a CAGR of 9.73% from 2025 to 2034. The North America market size surpassed USD 1.77 billion in 2024 and is expanding at a CAGR of 9.85% during the forecast period. The market sizing and forecasts are revenue-based (USD Million/Billion), with 2024 as the base year.
1.1. Research Objective
1.2. Scope of the Study
1.3. Definition
2.1. Research Approach
2.2. Data Sources
2.3. Assumptions & Limitations
3.1. Market Snapshot
4.1. Introduction
4.2. Market Classification and Scope
4.3. Industry Value Chain Analysis
4.3.1. Raw Material Procurement Analysis
4.3.2. Sales and Distribution Analysis
4.3.3. Downstream Buyer Analysis
5.1. COVID-19 Landscape: Sterile Injectables CDMO Industry Impact
5.2. COVID 19 - Impact Assessment for the Industry
5.3. COVID 19 Impact: Global Major Government Policy
5.4. Market Trends and Opportunities in the COVID-19 Landscape
6.1. Market Dynamics
6.1.1. Market Drivers
6.1.2. Market Restraints
6.1.3. Market Opportunities
6.2. Porter’s Five Forces Analysis
6.2.1. Bargaining power of suppliers
6.2.2. Bargaining power of buyers
6.2.3. Threat of substitute
6.2.4. Threat of new entrants
6.2.5. Degree of competition
7.1.1. Company Market Share/Positioning Analysis
7.1.2. Key Strategies Adopted by Players
7.1.3. Vendor Landscape
7.1.3.1. List of Suppliers
7.1.3.2. List of Buyers
8.1. Sterile Injectables CDMO Market, by Molecule Type
8.1.1. Small Molecules
8.1.1.1. Market Revenue and Forecast
8.1.2. Large Molecules
8.1.2.1. Market Revenue and Forecast
9.1. Sterile Injectables CDMO Market, by Product
9.1.1. Pre-filled Syringes
9.1.1.1. Market Revenue and Forecast
9.1.2. Vials and Ampoules
9.1.2.1. Market Revenue and Forecast
9.1.3. Specialty Injectables
9.1.3.1. Market Revenue and Forecast
9.1.4. Others
9.1.4.1. Market Revenue and Forecast
10.1. Sterile Injectables CDMO Market, by Service
10.1.1. Formulation Development
10.1.1.1. Market Revenue and Forecast
10.1.2. Analytical and Testing Services
10.1.2.1. Market Revenue and Forecast
10.1.3. Manufacturing
10.1.3.1. Market Revenue and Forecast
10.1.4. Packaging
10.1.4.1. Market Revenue and Forecast
10.1.5. Storage
10.1.5.1. Market Revenue and Forecast
10.1.5. Others
10.1.5.1. Market Revenue and Forecast
11.1. Sterile Injectables CDMO Market, by Therapeutic Area
11.1.1. Oncology
11.1.1.1. Market Revenue and Forecast
11.1.2. Cardiovascular Diseases
11.1.2.1. Market Revenue and Forecast
11.1.3. Central Nervous System Diseases
11.1.3.1. Market Revenue and Forecast
11.1.4. Infectious Disorders
11.1.4.1. Market Revenue and Forecast
11.1.5. Musculoskeletal Diseases
11.1.5.1. Market Revenue and Forecast
11.1.6. Others
11.1.6.1. Market Revenue and Forecast
12.1. Sterile Injectables CDMO Market, by Route of Administration
12.1.1. Subcutaneous (SC)
12.1.1.1. Market Revenue and Forecast
12.1.2. Intravenous (IV)
12.1.2.1. Market Revenue and Forecast
12.1.3. Intramuscular (IM)
12.1.3.1. Market Revenue and Forecast
12.1.4. Others
12.1.4.1. Market Revenue and Forecast
13.1. Sterile Injectables CDMO Market, by End-use
13.1.1. Pharmaceutical Companies
13.1.1.1. Market Revenue and Forecast
13.1.2. Biopharmaceutical Companies
13.1.2.1. Market Revenue and Forecast
13.1.3. Others
13.1.3.1. Market Revenue and Forecast
14.1. North America
14.1.1. Market Revenue and Forecast, by Molecule Type
14.1.2. Market Revenue and Forecast, by Product
14.1.3. Market Revenue and Forecast, by Service
14.1.4. Market Revenue and Forecast, by Therapeutic Area
14.1.5. Market Revenue and Forecast, by Route of Administration
14.1.6. Market Revenue and Forecast, by End-use
14.1.7. U.S.
14.1.7.1. Market Revenue and Forecast, by Molecule Type
14.1.7.2. Market Revenue and Forecast, by Product
14.1.7.3. Market Revenue and Forecast, by Service
14.1.7.4. Market Revenue and Forecast, by Therapeutic Area
14.1.8. Market Revenue and Forecast, by Route of Administration
14.1.8.1. Market Revenue and Forecast, by End-use
14.1.9. Rest of North America
14.1.9.1. Market Revenue and Forecast, by Molecule Type
14.1.9.2. Market Revenue and Forecast, by Product
14.1.9.3. Market Revenue and Forecast, by Service
14.1.9.4. Market Revenue and Forecast, by Therapeutic Area
14.1.10. Market Revenue and Forecast, by Route of Administration
14.1.11. Market Revenue and Forecast, by End-use
14.1.11.1.
14.2. Europe
14.2.1. Market Revenue and Forecast, by Molecule Type
14.2.2. Market Revenue and Forecast, by Product
14.2.3. Market Revenue and Forecast, by Service
14.2.4. Market Revenue and Forecast, by Therapeutic Area
14.2.5. Market Revenue and Forecast, by Route of Administration
14.2.6. Market Revenue and Forecast, by End-use
14.2.7.
14.2.8. UK
14.2.8.1. Market Revenue and Forecast, by Molecule Type
14.2.8.2. Market Revenue and Forecast, by Product
14.2.8.3. Market Revenue and Forecast, by Service
14.2.9. Market Revenue and Forecast, by Therapeutic Area
14.2.10. Market Revenue and Forecast, by Route of Administration
14.2.10.1. Market Revenue and Forecast, by End-use
14.2.11. Germany
14.2.11.1. Market Revenue and Forecast, by Molecule Type
14.2.11.2. Market Revenue and Forecast, by Product
14.2.11.3. Market Revenue and Forecast, by Service
14.2.12. Market Revenue and Forecast, by Therapeutic Area
14.2.13. Market Revenue and Forecast, by Route of Administration
14.2.14. Market Revenue and Forecast, by End-use
14.2.14.1.
14.2.15. France
14.2.15.1. Market Revenue and Forecast, by Molecule Type
14.2.15.2. Market Revenue and Forecast, by Product
14.2.15.3. Market Revenue and Forecast, by Service
14.2.15.4. Market Revenue and Forecast, by Therapeutic Area
14.2.16. Market Revenue and Forecast, by Route of Administration
14.2.16.1. Market Revenue and Forecast, by End-use
14.2.17. Rest of Europe
14.2.17.1. Market Revenue and Forecast, by Molecule Type
14.2.17.2. Market Revenue and Forecast, by Product
14.2.17.3. Market Revenue and Forecast, by Service
14.2.17.4. Market Revenue and Forecast, by Therapeutic Area
14.2.18. Market Revenue and Forecast, by Route of Administration
14.2.18.1. Market Revenue and Forecast, by End-use
14.3. APAC
14.3.1. Market Revenue and Forecast, by Molecule Type
14.3.2. Market Revenue and Forecast, by Product
14.3.3. Market Revenue and Forecast, by Service
14.3.4. Market Revenue and Forecast, by Therapeutic Area
14.3.5. Market Revenue and Forecast, by Route of Administration
14.3.6. Market Revenue and Forecast, by End-use
14.3.7. India
14.3.7.1. Market Revenue and Forecast, by Molecule Type
14.3.7.2. Market Revenue and Forecast, by Product
14.3.7.3. Market Revenue and Forecast, by Service
14.3.7.4. Market Revenue and Forecast, by Therapeutic Area
14.3.8. Market Revenue and Forecast, by Route of Administration
14.3.9. Market Revenue and Forecast, by End-use
14.3.10. China
14.3.10.1. Market Revenue and Forecast, by Molecule Type
14.3.10.2. Market Revenue and Forecast, by Product
14.3.10.3. Market Revenue and Forecast, by Service
14.3.10.4. Market Revenue and Forecast, by Therapeutic Area
14.3.11. Market Revenue and Forecast, by Route of Administration
14.3.11.1. Market Revenue and Forecast, by End-use
14.3.12. Japan
14.3.12.1. Market Revenue and Forecast, by Molecule Type
14.3.12.2. Market Revenue and Forecast, by Product
14.3.12.3. Market Revenue and Forecast, by Service
14.3.12.4. Market Revenue and Forecast, by Therapeutic Area
14.3.12.5. Market Revenue and Forecast, by Route of Administration
14.3.12.6. Market Revenue and Forecast, by End-use
14.3.13. Rest of APAC
14.3.13.1. Market Revenue and Forecast, by Molecule Type
14.3.13.2. Market Revenue and Forecast, by Product
14.3.13.3. Market Revenue and Forecast, by Service
14.3.13.4. Market Revenue and Forecast, by Therapeutic Area
14.3.13.5. Market Revenue and Forecast, by Route of Administration
14.3.13.6. Market Revenue and Forecast, by End-use
14.4. MEA
14.4.1. Market Revenue and Forecast, by Molecule Type
14.4.2. Market Revenue and Forecast, by Product
14.4.3. Market Revenue and Forecast, by Service
14.4.4. Market Revenue and Forecast, by Therapeutic Area
14.4.5. Market Revenue and Forecast, by Route of Administration
14.4.6. Market Revenue and Forecast, by End-use
14.4.7. GCC
14.4.7.1. Market Revenue and Forecast, by Molecule Type
14.4.7.2. Market Revenue and Forecast, by Product
14.4.7.3. Market Revenue and Forecast, by Service
14.4.7.4. Market Revenue and Forecast, by Therapeutic Area
14.4.8. Market Revenue and Forecast, by Route of Administration
14.4.9. Market Revenue and Forecast, by End-use
14.4.10. North Africa
14.4.10.1. Market Revenue and Forecast, by Molecule Type
14.4.10.2. Market Revenue and Forecast, by Product
14.4.10.3. Market Revenue and Forecast, by Service
14.4.10.4. Market Revenue and Forecast, by Therapeutic Area
14.4.11. Market Revenue and Forecast, by Route of Administration
14.4.12. Market Revenue and Forecast, by End-use
14.4.13. South Africa
14.4.13.1. Market Revenue and Forecast, by Molecule Type
14.4.13.2. Market Revenue and Forecast, by Product
14.4.13.3. Market Revenue and Forecast, by Service
14.4.13.4. Market Revenue and Forecast, by Therapeutic Area
14.4.13.5. Market Revenue and Forecast, by Route of Administration
14.4.13.6. Market Revenue and Forecast, by End-use
14.4.14. Rest of MEA
14.4.14.1. Market Revenue and Forecast, by Molecule Type
14.4.14.2. Market Revenue and Forecast, by Product
14.4.14.3. Market Revenue and Forecast, by Service
14.4.14.4. Market Revenue and Forecast, by Therapeutic Area
14.4.14.5. Market Revenue and Forecast, by Route of Administration
14.4.14.6. Market Revenue and Forecast, by End-use
14.5. Latin America
14.5.1. Market Revenue and Forecast, by Molecule Type
14.5.2. Market Revenue and Forecast, by Product
14.5.3. Market Revenue and Forecast, by Service
14.5.4. Market Revenue and Forecast, by Therapeutic Area
14.5.5. Market Revenue and Forecast, by Route of Administration
14.5.6. Market Revenue and Forecast, by End-use
14.5.7. Brazil
14.5.7.1. Market Revenue and Forecast, by Molecule Type
14.5.7.2. Market Revenue and Forecast, by Product
14.5.7.3. Market Revenue and Forecast, by Service
14.5.7.4. Market Revenue and Forecast, by Therapeutic Area
14.5.8. Market Revenue and Forecast, by Route of Administration
14.5.8.1. Market Revenue and Forecast, by End-use
14.5.9. Rest of LATAM
14.5.9.1. Market Revenue and Forecast, by Molecule Type
14.5.9.2. Market Revenue and Forecast, by Product
14.5.9.3. Market Revenue and Forecast, by Service
14.5.9.4. Market Revenue and Forecast, by Therapeutic Area
14.5.9.5. Market Revenue and Forecast, by Route of Administration
14.5.9.6. Market Revenue and Forecast, by End-use
15.1. Aenova Group
15.1.1. Company Overview
15.1.2. Product Offerings
15.1.3. Financial Performance
15.1.4. Recent Initiatives
15.2. Ajinomoto Bio-Pharma
15.2.1. Company Overview
15.2.2. Product Offerings
15.2.3. Financial Performance
15.2.4. Recent Initiatives
15.3. Alcami Corporation
15.3.1. Company Overview
15.3.2. Product Offerings
15.3.3. Financial Performance
15.3.4. Recent Initiatives
15.4. Baxter (Simtra BioPharma Solutions)
15.4.1. Company Overview
15.4.2. Product Offerings
15.4.3. Financial Performance
15.4.4. Recent Initiatives
15.5. Boehringer Ingelheim International GmbH
15.5.1. Company Overview
15.5.2. Product Offerings
15.5.3. Financial Performance
15.5.4. Recent Initiatives
15.6. Eurofins Scientific
15.6.1. Company Overview
15.6.2. Product Offerings
15.6.3. Financial Performance
15.6.4. Recent Initiatives
15.7. FAMAR Health Care Services
15.7.1. Company Overview
15.7.2. Product Offerings
15.7.3. Financial Performance
15.7.4. Recent Initiatives
15.8. Fareva Group
15.8.1. Company Overview
15.8.2. Product Offerings
15.8.3. Financial Performance
15.8.4. Recent Initiatives
15.9. Fresenius Kabi Contract Manufacturing (Fresenius Kabi AG)
15.9.1. Company Overview
15.9.2. Product Offerings
15.9.3. Financial Performance
15.9.4. Recent Initiatives
15.10. IDT Biologika GmbH
15.10.1. Company Overview
15.10.2. Product Offerings
15.10.3. Financial Performance
15.10.4. Recent Initiatives
16.1. Primary Research
16.2. Secondary Research
16.3. Assumptions
17.1. About Us
17.2. Glossary of Terms
For questions or customization requests, please reach out to us at sales@precedenceresearch.com
Plan your call and get expert insights!
Schedule a Meeting
No cookie-cutter, only authentic analysis – take the 1st step to become a Precedence Research client
Report Description
Get a Sample